Genocea Biosciences (GNCA) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Reports Second Quarter 2015 Financial Results
August 6, 2015 8:00 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the second quarter ended June 30, 2015.
"We were extremely pleased to report positive top-line results in May from our Phase 2 dose optimization trial of GEN-003, our immunotherapy against genital herpes, which improved upon the already attractive efficacy profile from our prior Phase 1/2a trial, said Chip Clark, president and chief executive officer of Genocea. In the fourth quarter of this year, we look forward to reporting... More
